|1.||Rodríguez-Baño, Jesús: 1 article (09/2015)|
|2.||Speer, Linda: 1 article (01/2015)|
|3.||Mackeen, A Dhanya: 1 article (01/2015)|
|4.||Packard, Roger E: 1 article (01/2015)|
|5.||Ota, Erika: 1 article (01/2015)|
|6.||Liu, Cui Hua: 1 article (01/2013)|
|7.||Li, Bin: 1 article (01/2013)|
|8.||Tsang, Alan K L: 1 article (01/2013)|
|9.||Yi, Yong: 1 article (01/2013)|
|10.||Wang, Qi: 1 article (01/2013)|
09/01/2015 - "The most promising candidates for invasive infections so far are β-lactam/β-lactamase inhibitor combinations and cephamycins. "
07/01/1995 - "However, cephamycins should be used with caution to treat infections caused by ESBL-producing K. "
11/01/1990 - "Role of new cephamycins in the management of obstetric and gynecologic infections."
09/01/2011 - "Increasing resistance to quinolones, aminoglycosides, and/or cephamycins in extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae exacerbates the already limited antibiotic treatment options for infections due to these microbes. "
06/01/1985 - "Cefbuperazone (BMY 25182), a new cephamycin, showed activity similar to those of moxalactam and other cephalosporin-cephamycins against aerobic and anaerobic bacteria from female genital tract infections. "
|2.||Urinary Tract Infections (Urinary Tract Infection)
09/01/1997 - "An Escherichia coli strain resistant to a broad spectrum of beta-lactams, including cephamycins, was isolated from a patient suffering from urinary tract infection. "
11/01/1985 - "Its efficacy in urinary tract infections is at least as good as cefoxitin, although in this and some other clinical areas its activity relative to that of other cephamycins and cephalosporins remains to be assessed. "
11/01/1989 - "A clinical isolate of Escherichia coli, strain CB-134, recovered in 1986 from an abdominal abscess, exhibited resistance to penams, oxyimino-beta-lactams including broad-spectrum cephalosporins (cefotaxime, ceftriaxone, ceftazidime), and aztreonam but remained susceptible to cephamycins (cefoxitin, cefotetan) and to moxalactam and imipenem. "
01/01/2013 - "Multiple logistic regression analysis revealed that certain clinical characteristics were associated with those prevalent STs such as: from ICU, from medical ward, from community acquired infection, from patients without heart disease, from patients with treatment success, susceptible to extended spectrum cephalosporin, susceptible to cephamycins, susceptible to fluoroquinolones, and with MDR. "
|5.||Wounds and Injuries (Trauma)
|1.||Cephalosporins (Cephalosporin Antibiotics)
|3.||Cefoxitin (Cefoxitin Sodium)